• 1
    Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
  • 2
    Andriole GL, Crawford ED, Grubb RL3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
  • 3
    Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003; 95: 868-878.
  • 4
    Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol. 2004; 172: 90-93.
  • 5
    Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001; 58: 411-416.
  • 6
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273: 289-294.
  • 7
    Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007; 25: 431-436.
  • 8
    Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006; 67: 316-320.
  • 9
    Whittemore AS, Cirillo PM, Feldman D, Cohn BA. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol. 2005; 174: 872-876; discussion 876.
  • 10
    Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med. 2008; 6: 6.
  • 11
    Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008; 26: 835-841.
  • 12
    Vickers AJ, Ulmert D, Serio AM, et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer. 2007; 121: 2212-2217.
  • 13
    Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden—an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol. 2003; 37: 112-119.
  • 14
    Ulmert D, Becker C, Nilsson JA, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at −20 degrees C. Clin Chem. 2006; 52: 235-239.
  • 15
    Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem. 1995; 41: 1115-1120.
  • 16
    Vaisanen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments. Anal Chem. 2006; 78: 7809-7815.
  • 17
    Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. New York: Oxford University Press; 2004.
  • 18
    Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979; 74: 829-836.
  • 19
    Lee WC. Probabilistic analysis of global performances of diagnostic tests: interpreting the Lorenz curve-based summary measures. Stat Med. 1999; 18: 455-471.
  • 20
    American Cancer Society. How is prostate cancer found? Available at: Accessed May 29, 2009.
  • 21
    Steuber T, Vickers A, Haese A, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer. 2007; 120: 1499-1504.
  • 22
    Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008; 6: 19.
  • 23
    Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994; 10; 1594-1598.
  • 24
    Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol. 2007; 41: 456-477.
  • 25
    Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008; 358: 910-919.
  • 26
    Eeles R, Giles G, Neal D, Muir K, Easton DF. Reply to Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008; 40: 1035-1036.
  • 27
    Gallagher DJ, Vijai J, Cronin AM, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res. 2010; 16: 2819-2832.
  • 28
    Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet. 2008; 40: 316-321.
  • 29
    Ahn J, Berndt SI, Wacholder S, et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008; 40: 1032-4, author reply 35-36.
  • 30
    Klein RJ, Hallden C, Cronin AM, et al. Blood biomarker levels to aid discovery of cancer-related single nucleotide polymorphisms: kallikreins and prostate cancer. Can Prev Res. 2010; 3: 611-619.
  • 31
    Roobol MJ, Grenabo A, Schroder FH, Hugosson J. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst. 2007; 99: 1296-1303.